Alnylam Pharmaceuticals, Inc. (ALNY)
309.66
-10.47
(-3.27%)
USD |
NASDAQ |
Apr 17, 16:00
310.41
+0.75
(+0.24%)
After-Hours: 20:00
Alnylam Pharmaceuticals SG&A Expense (Quarterly) : 325.37M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Pfizer Inc. | 4.162B |
| Gilead Sciences, Inc. | 4.418B |
| Ionis Pharmaceuticals, Inc. | 130.00M |
| Eli Lilly & Co. | 3.132B |
| Regeneron Pharmaceuticals, Inc. | 775.00M |